FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 354:1871-1873 May 4, 2006 Number 18 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

Two recent developments — increased awareness of the complications that may follow egg donation for stem-cell research and the disastrous consequences of a clinical trial of the humanized monoclonal antibody TGN1412 in which healthy volunteers nearly died (discussed in this issue by Wood and Darbyshire) — have focused renewed attention on the long-standing issue of compensation for injured research subjects.¹ In the United States, despite decades of discussion and recommendations by national commissions, sponsors and institutions are not required to provide either free medical care or compensation, although some do. In contrast, many European countries mandate the provision of clinical-trials . . . [Full Text of this Article]

Source Information

Dr. Steinbrook (rsteinbrook@attglobal.net) is a national correspondent for the Journal.

This article has been cited by other articles:

• Thatte, U M, Kulkarni-Munshi, R, Kalekar, S A (2009). Review of policies for injuries to research participants in India. J. Med. Ethics 35: 133-139 [Abstract] [Full Text]  
• Elliott, C., Abadie, R. (2008). Exploiting a Research Underclass in Phase 1 Clinical Trials. NEJM 358: 2316-2317 [Full Text]  
• Bramstedt, K. A. (2007). Recruiting Healthy Volunteers for Research Participation via Internet Advertising. Clin Med Res 5: 91-97 [Abstract] [Full Text]